Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids
- 387 Downloads
The role of sclerostin on bone metabolism and its relation to sex steroids in patients with prostate cancer (PC) is not well known. We found that sclerostin levels are significantly increased in PC patients, particularly in those with androgen deprivation therapy (ADT), and there is an inverse relationship between sclerostin levels and testosterone.
Recent studies have evaluated sclerostin levels in bone diseases as osteoporosis. However, there are few data in PC patients, particularly in patients with hypogonadism related to ADT. The aim of the present study was to compare serum sclerostin levels in ADT/non-ADT-treated PC patients and healthy controls and to evaluate their relationship with sex steroids and bone metabolism.
We performed a cross-sectional study involving 81 subjects: 25 ADT-treated PC patients, 34 PC patients without ADT treatment, and 22 healthy controls. We measured serum sclerostin levels, bone turnover markers, bone mineral density (BMD) in all individuals, and sex steroids levels in PC patients.
Serum sclerostin levels were significantly higher in PC patients compared to those in control subjects. ADT-treated patients had significantly higher sclerostin levels than PC patients without ADT treatment: ADT 64.52 ± 27.21 pmol/L, non-ADT 48.24 ± 15.93 pmol/L, healthy controls 38.48 ± 9.19 pmol/L, p < 0.05. In PC patients, we found a negative relationship between serum sclerostin levels and androgens after age adjustment (total testosterone: r = −0.309, p = 0.029; bioavailable testosterone: r = −0.280, p = 0.049; free testosterone: r = −0.299, p = 0.035). We did not observe any relationship between sclerostin levels and bone turnover markers or BMD in any group.
Circulating sclerostin levels are significantly increased in patients with PC and particularly in those receiving ADT. The inverse relationship between serum sclerostin and testosterone in these patients suggests that androgens are key regulators of bone metabolism in this population.
KeywordsBone metabolism Hypogonadism Prostate cancer Sclerostin Sex steroids
We thank Amanda Rocío Gonzalez (Fundación Pública Andaluza para la Investigación Biosanitaria de Andalucía Oriental Alejandro Otero (FIBAO) from Hospital Clínico San Cecilio, Granada) for her statistical advice. This work was support in part by Consejería de Salud y Bienestar Social (Junta de Andalucía) Grant (PI05142012) and Fondo de Investigación Sanitaria (Instituto Carlos III) Grants (PI12/02141) and RETICEF (RD06/0013/1014-RD12/0043/0014).
Conflicts of interest
- 16.Spanjol J, Djordjević G, Markić D, Klarić M, Fuckar D, Bobinac D (2010) Role of bone morphogenetic proteins in human prostate cancer pathogenesis and development of bone metastases: immunohistochemical study. Coll Antropol 2:119–125Google Scholar